Study #2019-0421
A Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Mantle Cell Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Acalabrutinib
Description
This phase II trial studies how well acalabrutinib works in treating patients with mantle cell lymphoma that cannot tolerate ibrutinib. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mantle Cell Lymphoma
Study phase:
Phase II
Physician name:
Preetesh Jain
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-705-0985
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.